Navigation Links
Pharmasset to Present at Cowen & Company's Health Care Conference on Tuesday, March 18th
Date:3/10/2008

PRINCETON, N.J., March 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at Cowen & Company's 28th Annual Health Care Conference being held March 17-20, 2008 at Boston Marriott Copley Place in Boston, MA. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Tuesday, March 18, 2008 from 3:55 PM to 4:00 PM (ET) in Salon C.

To access a simultaneous webcast of Mr. Price's overview of the company via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
2. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
3. Pharmasset Reports Fiscal Year End 2007 Financial Results
4. Pharmasset Appoints Michael Rogers as Chief Development Officer
5. Pharmasset to Present at Three Investor Conferences in November 2007
6. Pharmasset Accesses up to $30 Million of Working Capital
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
8. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Ky. , Jan. 16, 2017  Eurofins Genomics ... which will allow more customers to receive their primers ... premium or compromise in quality found with other providers. ... the United States at no additional fee. ... of routine genetic studies, including DNA sequencing, genotyping, site-directed ...
(Date:1/13/2017)... , Jan 13, 2017 Research and Markets ... report to their offering. ... The global biopolymers market to grow at a CAGR of 16.83% during ... and the growth prospects of the global biopolymers market for 2017-2021. To ... sale of sales of biopolymer products. The report also includes a a ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... VTI’S INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the ... InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
Breaking Biology Technology:
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
Breaking Biology News(10 mins):